NEW YORK – Siemens Healthineers has been granted funding from the Gates Foundation to support development of a maternal health screening tool, the firm announced on Friday. The total amount of the ...

Altai Capital said last month it had "serious concerns about the company’s significant share price underperformance." ...

In a presentation, executives discussed upcoming data readouts and their potential effect on reimbursement for the firm's FirstLook Lung test.

The firm's CEO expects lab capital expenditures to return to normal by the second half of 2026 as the overall life science ...

NEW YORK — Several Delta Dental dental health plan administrators said on Thursday that they will begin coverage of OraLiva's oral cancer test.

The bill was one of several discussed during a Thursday hearing by the Health Subcommittee of the House of Representatives' ...

Chairman and CEO Adam Schechter said that deals may open up as hospital systems grow concerned about Medicaid cuts and the end of Affordable Care Act subsidies.

The company said it will use the money raised from a convertible notes offering to advance its proteomics platform.

Diagnostics is already operating somewhat separately from the firm's other two business units under its new organizational structure, company officials said.

President and CEO Jim Davis said he believes PAMA reform will pass this year but said another temporary delay will likely be needed to postpone cuts slated for February 1.

The tests run on the company's TruVerus benchtop instrument, which provides results from a blood sample in minutes.

The firm expects 2026 revenue of $860 million to $880 million, reflecting an increase of approximately 6 percent over its preliminary 2025 revenue.